Tris Pharma Inc patents expiration
1. Dyanavel Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675703 | TRIS PHARMA INC | Modified release formulations containing drug - ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US8597684 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US8883217 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US10086087 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US8062667 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(5 years from now) | |
| US11590228 | TRIS PHARMA INC | NA |
Sep, 2036
(12 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 19 October, 2015
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
DYANAVEL XR family patents
2. Dyanavel Xr 10 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8337890 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US9675704 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US11590081 | TRIS PHARMA INC | NA |
Sep, 2038
(14 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
DYANAVEL XR 10 family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic